Check 35,000+ stocks against 26 valuation models and 37 quality factors

SSY Group Ltd (2005) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of SSY Group Ltd HK$2.66, price HK$2.83, upside -5.8%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · HK · ISIN KYG8406X1034

SG Thin data Sep 27, 2026

SSY Group Ltd

2005 · HK

Low PriorityFair Value upside is limited and quality is weak.

·Fair value HK$2.66 · Fairly valued (−5.8%)

!Quality 48/100

!Weak Growth (revenue 5y −0.5 %/yr)

✓Solidly profitable · 11.3% net margin (TTM)

✓Low debt · generates free cash flow

✓2.8% dividend yield · Sustainable

✓Ranks above peers (10/15)

!Narrow moat 40/100

!Evidence only low, so the estimate is less certain

!Weak on valuation: 26 out of 100

!Weak on past: 26 out of 100

26 models, one by oneBear HK$1.57 to bull HK$3.85 Growth analysisrevenue history, year by year Quality 48/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch SSY Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$2.02 – HK$6.72 · fair‑value band HK$1.57 – HK$3.85 · the HK$2.83 price screens above the HK$2.66 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow SSY Group in your weekly email

Every Wednesday you see whether SSY Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; research, development of biotechnology and related roducts; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. SSY Group Limited was founded in 1999 and is headquartered in Wan Chai, Hong Kong.

Stock analysis

SSY Group Ltd (2005) currently trades at HK$2.83, while our model-based Fair Value estimate is HK$2.66, so the stock looks roughly fairly valued today (gap 6.2%).

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$3.21 per share, and 9 of the 26 models we run sit above the HK$2.83 price.

Bear case: the Earnings-Based group reads lowest at HK$1.16, and 17 of the 26 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$1.57 (bear) to HK$3.85 (bull), the price of HK$2.83 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

SSY Group Ltd reported revenue of HK$4.2B in FY2025 versus HK$5.4B in FY2021, a compound −6.1%/yr. Reported net income was HK$471M in FY2025, compounding −12.0%/yr from FY2021.

Key figures

Market cap HK$8.3B (≈ $1.1B) · P/E ratio 17.5 · P/S ratio 1.98 · EPS (TTM) HK$0.1613 · Dividend yield 2.8% · Net margin 11.3% · Return on equity 6.4% · Return on assets (EBIT) 10.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 40% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −6%, 2005 screens cheaper than that median.

Fair Value models

Bear HK$1.57 Fair Value HK$2.66 Bull HK$3.85

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0150 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$1.12 HK$1.73 HK$2.54 80

Growth DCF HK$1.13 HK$1.65 HK$2.30 79

Owner Earnings HK$2.08 HK$3.12 HK$4.54 76

All 26 models by family

DCF Models

FCF DCF HK$1.12 HK$1.73 HK$2.54 80

Owner Earnings HK$2.08 HK$3.12 HK$4.54 76

5Y Revenue Exit HK$1.48 HK$2.55 HK$3.93 71

5Y EBITDA Exit HK$2.45 HK$4.38 HK$6.66 74

5Y P/E Exit HK$1.78 HK$3.12 HK$4.54 70

10Y Revenue Exit HK$1.27 HK$2.15 HK$3.36 65

10Y EBITDA Exit HK$1.88 HK$3.32 HK$5.28 67

10Y P/E Exit HK$1.49 HK$2.52 HK$3.79 63

Earnings-Based

Graham-Dodd HK$1.11 HK$3.62 HK$4.84 64

Lynch FV HK$0.8100 HK$1.16 HK$1.51 61

PEG = 1.0 HK$0.8100 HK$1.16 HK$1.51 57

EPV HK$1.35 HK$1.56 HK$1.73 74

Dividend Discount

Gordon GGM HK$1.15 HK$2.07 HK$2.85 68

DDM Multi-Stage HK$1.15 HK$1.82 HK$2.21 67

Multiples

P/E Multiple HK$2.69 HK$3.58 HK$4.48 63

P/S Multiple HK$2.08 HK$2.77 HK$3.46 58

P/B Multiple HK$2.08 HK$2.77 HK$3.46 55

EV/EBIT HK$2.61 HK$3.53 HK$4.46 66

EV/EBITDA HK$3.77 HK$5.08 HK$6.39 67

EV/Revenue HK$1.82 HK$2.66 HK$3.51 53

Asset-Based

NCAV (Graham) HK$1.26 HK$1.69 HK$2.53 54

Growth DCF

Growth DCF HK$1.13 HK$1.65 HK$2.30 79

Rev-Margin DCF HK$1.48 HK$2.54 HK$3.77 72

Economic Profit

Residual Income HK$1.92 HK$1.98 HK$2.12 76

ROIC Compounder HK$1.35 HK$1.56 HK$1.73 72

Growth Earnings

Growth-Adj P/E HK$2.25 HK$3.21 HK$4.17 67

Open the full fair value analysis →

Notify me when 2005 reaches fair value

Put 2005 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 48/100

Of which business quality 48 · Market factors (momentum, volatility) 63

Profitability 32

Margins and returns on capital today

Quality Growth 1

Are margins and returns improving?

Cashflow 44

Earnings quality: real cash, not paper profit

Fin. Strength 59

Balance sheet, leverage, solvency risk

Investment 71

Disciplined investing over empire-building

Low Volatility 84

Calm price path (market factor)

Momentum 56

Price trend over the last 3–12 months (market factor)

52W Momentum 51

Distance to the 52-week high (market factor)

Net Issuance 90

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100

Revenue is shrinking: the last year, the last three and the last five years are all negative.

Revenue growth 1 year

−27.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−13.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−0.5%

Start year 2020 (pandemic). Over 10 years: +6.5% a year

Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+7.1%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

−6.3%

Earnings growth per share plus dividend.

Earnings per share, growth per year−9.1%

Dividend (yield on the price)2.8%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−9.1% vs −0.7%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 15%

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+21.7%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+12.3%

Yearly sales growth analysts expect, extended to five years.

After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +19.2% a year for the price and +9.9% for the forecasts.

Forecast 2026 (sales)+16.8%

Forecast 2027 (sales)+13.3%

Projected 2028 (sales)+11.9%

Projected 2029 (sales)+10.4%

Projected 2030 (sales)+9.0%

Watch 2005, get fair value alerts →

Compare SSY Group Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 619 stocks

Beats the industry median on 10/15 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 48 · Below median

Fair Value upside −5.8% · Above median

Profitability

Return on equity (TTM) 6.4% · Below median

Return on assets 2.9% · Above median

Net margin (TTM) 11.3% · Above median

Operating margin (TTM) 11.1% · Above median

Growth and dividend

Revenue growth −17.1% · Bottom 25%

Dividend yield (TTM) 2.8% · Above median

Balance sheet

Debt / equity 0.31× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 17.5× · Cheaper than median

P/B 1.13× · Cheaper than median

P/S (TTM) 1.99× · Cheaper than median

P/FCF 27.6× · Pricier than median

EV/EBITDA 8.5× · Cheaper than median

PEG 0.44× · Cheapest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)26 · sector 14

FUTURE (revenue growth)0 · sector 19

PAST (return on equity)26 · sector 26

HEALTH (low debt)85 · sector 96

DIVIDEND (yield)57 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Merck KGaA MRK	€135.00	€108.94	−19%
Takeda Pharmaceutical Company TAK	$18.90	$11.45	−39%
Teva Pharmaceutical Industries Limited TEVA	$39.19	$20.88	−47%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,852	₹1,979	+7%
Galderma Group GALD	CHF 163.00	CHF 110.32	−32%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥44.86	¥49.35	+10%
Haleon plc HLN	$9.26	$8.49	−8%
Sandoz Group SDZ	CHF 71.16	CHF 40.32	−43%
Zoetis Inc ZTS	$70.30	$110.50	+57%
Divi's Laboratories Limited DIVISLAB	₹9,620	₹1,871	−81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SSY Group Ltd · Fair Value
HK$2.66 −6%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/2005" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">SSY Group Ltd · Fair Value</span><br><b style="font-size:20px">HK$2.66</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−6%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "SSY Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2005

Frequently asked questions

Is SSY Group Ltd (2005) overvalued or undervalued?

As of Sep 27, 2026, our model estimates a fair value of HK$2.66 versus a price of HK$2.83, about −6% upside (fairly valued).

What is the fair value of 2005?

Our model-based fair value for SSY Group Ltd is HK$2.66 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$2.83.

What is the quality score of 2005?

SSY Group Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for SSY Group Ltd (2005)?

Our model-based price target is the fair value of HK$2.66 (as of Sep 27, 2026) from 26 valuation models. Cautious scenario HK$1.57, optimistic scenario HK$3.85. It is a calculation from audited fundamentals, not an analyst target.

What is the SSY Group Ltd stock forecast for 2026?

Our models put fair value at HK$2.66, about −6% upside versus a price of HK$2.83 (fairly valued). Cautious scenario HK$1.57, optimistic scenario HK$3.85. The calculation is refreshed regularly with new filings.

What is the revenue of SSY Group Ltd (2005)?

SSY Group Ltd reported trailing-twelve-month revenue of about HK$4.2B (latest available figure, as of Sep 27, 2026).

Does SSY Group Ltd pay a dividend?

SSY Group Ltd currently shows a dividend yield of about 2.83% relative to its recent price (as of Sep 27, 2026).

What growth is priced into SSY Group Ltd (2005)?

For today's price to be fair in a discounted-cash-flow model, SSY Group Ltd would have to grow free cash flow by +21.7 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.5 % per year. As of Sep 27, 2026.

What discount rate (WACC) does the fair value of 2005 use?

Our models discount SSY Group Ltd at 10.3 %: a base by market capitalisation (small), damped by beta 0.44, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SSY Group Ltd that is +21.7 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.

How much growth has SSY Group Ltd (2005) delivered so far?

Over the past 5 years revenue at SSY Group Ltd grew -0.5 % a year. The price currently implies +21.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of SSY Group Ltd (2005) growing?

The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into SSY Group Ltd (+21.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of SSY Group Ltd (2005)?

The free-cash-flow yield on the price is 3.62 %: that much free cash flow SSY Group Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of SSY Group Ltd (2005)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SSY Group Ltd it is HK$2.66 per share (as of Sep 27, 2026), against a price of HK$2.83. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is SSY Group Ltd stock overvalued or undervalued in 2026?

As of Sep 27, 2026, 2005 trades above its calculated fair value: price HK$2.83, fair value HK$2.66, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 2005?

No. The price is what the market pays today (HK$2.83); the fair value is what the company's own numbers justify (HK$2.66). For SSY Group Ltd the two are HK$0.1650 per share apart. That gap is exactly why we show both numbers side by side.

How much is SSY Group Ltd worth?

The market values SSY Group Ltd at about HK$8.3B (market capitalisation, as of Sep 27, 2026). Per share that is HK$2.83; our models calculate a fair value of HK$2.66 per share.

What do the bullish and bearish scenarios say about 2005?

Our models span a range for SSY Group Ltd: cautious scenario HK$1.57, base HK$2.66, optimistic HK$3.85 per share (as of Sep 27, 2026, price HK$2.83). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 2005?

SSY Group Ltd trades at a price-to-earnings ratio of 17.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$2.66 is built from several models across several years. Other multiples: PEG 0.4, P/B 1.1, P/S 2.0, EV/EBITDA 8.5.

What is the PEG ratio of 2005?

The PEG ratio of SSY Group Ltd is 0.44 (P/E divided by earnings growth, as of Sep 27, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of SSY Group Ltd (2005)?

Balance-sheet figures for SSY Group Ltd (as of Sep 27, 2026): return on equity 6.4%, debt of 0.31 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.

How far is 2005 from its 52-week high?

SSY Group Ltd trades at HK$2.83, about 10% below its 52-week high of HK$3.13 and 40% above the low of HK$2.02 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.66 is for.

Which stocks are comparable to SSY Group Ltd?

From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is SSY Group Ltd stock attractive at the current price?

The data as of Sep 27, 2026: price HK$2.83, calculated fair value HK$2.66 (−6%), Quality Score 48/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 2005 calculated?

We run SSY Group Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$2.66, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.7 % above its aggregate fair value. SSY Group Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of SSY Group Ltd (2005)?

The closing price on Sep 30, 2026 was HK$2.83. Our model-based fair value is HK$2.66, about −6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with SSY Group Ltd right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$1.57 to HK$3.85) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Where does the earnings growth of SSY Group Ltd (2005) come from?

Earnings per share at SSY Group Ltd grew +7.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +10.3 %, EBIT margin −2.4 %, tax rate −0.1 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of SSY Group Ltd

How large is the market capitalisation of SSY Group Ltd (2005)?

The market capitalisation of SSY Group Ltd is HK$8.3B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of SSY Group Ltd (2005)?

The price-to-sales ratio of SSY Group Ltd is 1.98 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of SSY Group Ltd (2005)?

Earnings per share at SSY Group Ltd are HK$0.1613 (price ÷ EPS = P/E 17.5). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of SSY Group Ltd (2005)?

The dividend yield of SSY Group Ltd is 2.8% (payout 49.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of SSY Group Ltd (2005)?

The net margin of SSY Group Ltd is 11.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of SSY Group Ltd (2005)?

The return on equity (ROE) of SSY Group Ltd is 6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of SSY Group Ltd (2005)?

On an EBIT basis the return on assets of SSY Group Ltd is 10.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of SSY Group Ltd (2005)?

The operating margin of SSY Group Ltd is 11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at SSY Group Ltd (2005)?

Revenue at SSY Group Ltd is growing −17.1% versus a year earlier (3y avg −13.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at SSY Group Ltd (2005)?

Earnings per share at SSY Group Ltd are growing −49.5% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does SSY Group Ltd (2005) carry?

The net debt of SSY Group Ltd is HK$2.2B (fiscal year 2025, ≈ 7.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch SSY Group Ltd in the live analysis

One click puts SSY Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.